Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants

Summary

This is a phase 1, randomized, double-blind multi-center, placebo-controlled trial in Japan to evaluate the safety and immunogenicity of HIL-214 in healthy infants 5 months of age (-14/+14 days) at first trial vaccine administration. In this protocol, because the trial is blinded, trial vaccine refers to both the investigational vaccine (HIL-214) and placebo.

Timeline

Start

2023-08-18

Primary completion

2024-05-27

Completion

2024-05-27

Drugs

Indications